Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i-
For example, you could have suggested, "ILT, I believe you made a mistake believing you were replying to me." To which I would have replied, "Sorry, apparently I made a mistake"
i-
Did I say the Fish Oil industry lead the corruption?
r-
I am not one for conspiracy theories but the forces that have conspired to destroy and discredit Vascepa are clearly winning. ... As all of us know all too well, Amarin is a tiny player that barely has any market share. This compared to the fish oil industry that is several billion dollars and has zero data to say their product actually works, and more likely is causing real harm.
r-
Zoey Becker is off ...
With the company’s sales presence in Germany suspended, Amarin finds itself in a tough spot as it wages on with the launch.
Amarin expects the reimbursement talks to wrap up in November.
It’s also working on launch plans for Sweden
D-
Packaging problem, insert problem, capsule labelling problem?
Packaged product damaged during shipping or in storage?
Couldn't be an api or capsule problem, could it?
QA would have caught those problems.
inventory that was damaged by one of our third party suppliers
C-
Thx, but on the other hand I was way-off re. the ER.
I will analyze the 10-Q during the weekend and will try to to figure out the "answer" and to understand some strange thing ... eg.: "Amarin recorded a charge of $9.6 million related to unsellable inventory, which is not related to product dating ... this charge was a result of inventory that was damaged by one of our third party suppliers and caused the inventory not to be our quality standards." ... WTF???!!!
In my world it is not a pure $9.6 million cost ... Where is the $9.6 (+"recompense") other revenue paid by the third party suppliers who damaged the inventory ...
Best,
G
B-
I read this part to be the amount that AMRN would have to purchase contractually going forward and not with this one time quality issue.
The Company has a total of approximately $81.5 million in future contractual purchase obligations without consideration to ongoing discussions with other suppliers.
B-
They said 15 million had to be written off I think right?
The Company also reviewed its contractual supplier purchase obligations and has taken steps to amend supplier agreements to align supply arrangements with current and future market demand resulting in a charge of $15.0 million recognized within Cost of goods sold - restructuring inventory on the condensed consolidated statement of operations.
l-
I'm not speaking for HDG, but he posted something a few wks ago about no APIwill delivered this qtr.
g-
HDG, do you know the minimum IPE raw material purchase requirement for the rest of 2022?
z-
2022 Q1 results stimulated the fear of an Amarin bankruptcy by the market...Q2 results will show that fear to be unfounded...and the stock will tick up due better results in Q2 than in Q1, stimulating the expectation of still better results during the year and beyond.
z-
See update at the bottom
Again and I hope we can finally put this to rest
If it’s not in the US product it is not in the EU product.
Vazkepa
The finished product is presented as soft capsules containing 998 mg of icosapent ethyl as active
substance.
...
Printing ink: titanium dioxide, propylene glycol, and hypromellose
If it’s printed on the pill it has to be on the US label and it’s not, at least not on the label from the bottle I purchased 80 days ago.
n-
most of us do not agree with the report that Vascepa capsule content includes TiO2.
The only white I see is in the ink that appears in the TM Vascepa printed on the exterior of the capsule wall— de minimus.
Vazkepa
The finished product is presented as soft capsules containing 998 mg of icosapent ethyl as active
substance.
...
Printing ink: titanium dioxide, propylene glycol, and hypromellose
s-
Well done.
Best,
G
n-
What would the FDA Commissioner, a cardiologist, do if presented with a petition to ban/withdraw approval of the 2 gVs that also contain TiO2?
UPDATE:
I also came across that listed on a search result. BUT THATS FALSE! GOOGLE NEEDS TO REMOVE THAT. THAT'S SLANDER AT BEST.
https://www.ema.europa.eu/en/documents/assessment-report/vazkepa-epar-public-assessment-report_en.pdf" rel="nofollow" target="_blank" >https://www.ema.europa.eu/en/documents/assessment-report/vazkepa-epar-public-assessment-report_en.pdf[tag]Vazkepa
The finished product is presented as soft capsules containing 998 mg of icosapent ethyl as active
substance.
...
Printing ink: titanium dioxide, propylene glycol, and hypromellose[/tag]
Ok, thank goodness. I don't see Titanium Dioxide on Amarin's Label. Titanium Oxide "is" listed in Generics. This is a BIG DEAL.
Someone recently sued the manufacturer of Snickers or Skittles? for having that ingredient. Something that the manufacturer either downplayed or didn't address. This lawsuit was recently filed.
i-
Look at the bright side. At this rate, Generics will overtake the brand, so proving infringement should be a lock.
No question about that, but Hikma was taken off the infringement suit. Everything has been turned upside down when it cones to Amarin.
Are they just saying that the Generics are only making the drug available and nit inducing? Why didn’t that work for Teva vs GSK?
That's the billions of dollars question?
N-
If BASF wasn't under contract to supply Amarin, why wouldn't they be supplying the generic companies?
Points out that epadel api can't be changed over to vascepa api as it's different & then would need to be further approved by FDA (DMF)..(I believe that's a shot across bow to BASF). Says suppliers have told us they've been approached by generics & turned them down
Nope. It needs to be addressed still. BASF was once under contract as an API supplier to AMRN and they until recently advertised API for epadel and Vascepa on their website until the Vascepa reference disappeared after Amarin was notified. Coincidence?
r-
could the “awful inventory management” be related to JT trying to tie us all available supply of API to keep it away from the Generics
Something I believe Amarin is currently being sued for.
K-
Would be gr8 if they limited purchases and really worked down their inventory
C-
So, the absolute minimum obligation is $49m. Since they purchased $72m in Q1, is it theoretically possible that they made zero purchases in Q2?
over the term of such agreements
g-
HDG, do you have an estimate of Amarin's annual cash outlay required to meet the minimum purchase agreement for IPE from suppliers
l-
who do you think prompted AF or MH to write it?
l-
why doesn't amarin advertise to the public about their miracle drug??? Is there any logical explanation?
Money or lack there of??
Or is amarin afraid of another short attack?
C-
The beat of expectation
- Revenue: $88.34M (72.7 / 106)
- EPS: -0.06 (-0,10 / -0.04)
could help (could give an initial boost ... but it could be short lived).
Best,
G
My Q2 Net (Product) Revenue forecast: $113.800k ($113.142 - 114.477k)
vs Q2 2021: - $39.973k / - 25.99%
vs Q1 2022: + $19.814k / + 21.08%
Best,
G
l-
doesn't that include marketing to the public as well as prescribers
District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin's lead product, Vascepa®(icosapent ethyl) capsules, that are not covered by current FDA-approved labeling for the drug so long as the promotion is truthful and non-misleading.
l-
So what happened to their 1st amendment victory
r-
Furthermore - IIRC - the current decision is for England, Wales and Northern Ireland. Scotland has a separate process / authority.
Best,
G
b-
Yes, it was powered for 15%.
Best,
G
M-
Thx.
Best,
G
K-
Duke. That data imho is misleading.
The Q1 report detailed the % covered by exclusivity agreements… 45% IIRC
Duke. didn't KM say 45% of their scripts were thru exclusivity deals ? If so that doesn't match your figures does it ?
As of March 31, 2022, through our offerings designed to be competitive with the current market landscape, we expanded coverage to approximately 45% of the total commercial and Medicare Part D lives on a weighted average basis, with VASCEPA as the exclusive IP product.
d-
Nope ... my promise - to post it "today" - kept me up ... I like to keep my promise ... if I could ...
Furthermore I started my training camp (avoid jet lag) since two kick-off time (1pm and 3 / 3:05 / 3:25 pm Sunday) fit to my time zone, but - usually - I watch all kick-off time (5 / week)
Best,
G
K-
The US had / has positive contribution margin, defined as U.S. gross profit less U.S. sales and marketing-related expenses, in the U.S.
2021: $200+M
New "2021": $66+M (same script, but with 2022 Net Revenue / bottle)
After the $30 million reduction in annual marketing expenses and the approximately $100 million in cost savings they have to reach $168M Net Revenue to be breakeven.
"Annualized" contribution margin US (flat - Q1 - revenue, but inc. the cost savings) is $162+M ... to keep the $200+M they have to reach $439+M Net Revenue (lower by 26% / $150+M than in 2021) ... it is doable.
Best,
G
L-
a.) not necessary
b.) what is the special function that deliver a post to you from blocked poster ....?
Best,
G
ps.: As I wrote ... 2:54 AM here ... So do not take it personal, just as a "fun"
i-
Thanks, but
I disagree with your expected downside though.
I do not rule out a negative market reaction
I belief everyone is expecting a crap quarter.
K-
Why would Kaiser ( known for driving costs down by using generic ) be using brand V instead of generic V ?
Because
1) they know their CAD patients like me are only using it for the R-It indication … so don’t want to be dragged into a HealthNet like court case
2) AMRN gave them a lower price then the generics
3) combination of 1) and 2)
The exclusivity deals are de facto generic deals .
Name any Co making significant profit selling generics
i-
Much better to analyze any potential investment (AMRN definitely is one of these) before you are in ... In my case: in again. The "who is not even invested in the stock" is the current status I was in more than one times ...
Best,
G
W-
Does anyone know the reason Fintel is showing the Sarissa Capital with zero shares?
On June 15, 2022, Sarissa Capital issued a press release indicating how the Reporting Persons intend to vote at the upcoming annual meeting of the Issuer and the reasons therefor. A copy of the press release is attached as Exhibit 2 hereto.